000			02495na a2200253 4500
003			H12O
005			20180417112253.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aGutiérrez Solís, Elena _92028 _eNefrología
100			_983 _aMorales Ruiz, Enrique _eNefrología
100			_aPraga Terente, Manuel _91488 _eNefrología
245	0	0	_aHepatitis C-induced renal disease in patients with AIDS: an emergent problem. _h[artículo]
260			_bContributions to Nephrology, _c2012,
300			_a176:24-34.
500			_aFormato Vancouver: Praga M, Gutiérrez Solís E, Morales E. Hepatitis C-induced renal disease in patients with AIDS: an emergent problem. Contrib Nephrol. 2012;176:24-34.
501			_aPMID: 22310778
504			_aContiene 30 referencias
520			_aCryoglobulinemic membranoproliferative glomerulonephritis (MPGN) is the more characteristic renal disease associated with hepatitis C virus (HCV) infection. Patients infected with human immunodeficiency virus (HIV) can present, in addition to HIV-associated nephropathy, different types of immune complex glomerulonephritis, including MPGN, IgA nephropathy, non-collapsing focal segmental glomerulosclerosis, membranous nephropathy and lupus-like glomerulonephritis. On the other hand, the incidence of hypertensive nephrosclerosis, diabetic nephropathy and decreased renal function similar to that of elderly patients is increasingly recognized among HIV-infected patients. In spite of the fact that HCV coinfection in HIV patients is a very common problem, affecting approximately 30% of HIV-infected patients, information about the role of HCV in renal diseases of HIV-infected patients is scant. A large proportion of HIV patients with glomerular diseases are coinfected with HCV, and the latter is likely the responsible agent in those cases of cryoglobulinemic MPGN reported in HIV-infected patients. Participation of HCV in other types of HIV-related glomerular diseases is uncertain. Patient and renal survival in glomerular diseases of patients coinfected with HIV and HCV is very poor, but some studies suggest that antiretroviral therapy might change this dismal prognosis. Information about the effect of specific anti-VHC therapy or immunosuppressive agents in these patients is very limited.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3093.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c3093 _d3093